Metastatic renal cell carcinoma : Therapeutic concepts for non-medicinal ... - UroToday PDF Print
UroToday
Metastatic renal cell carcinoma has a poor prognosis with a median overall survival rate of approximately 2 years. The current standard medicinal therapy includes the use of tyrosine kinase inhibitors or antiangiogenic substances, such as VEGF receptor

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.